The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Let ...

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinica ...

Supreme Court Wrestles With Judges’ Power to Freeze Government Actions Nationwide The Supreme Court heard arguments in a case with potentially major implications for the power of federal judges ...

Gain insights, see trends and get real-time updates when you securely link or manually add your brokerage accounts.